U.S. Food and Drug Administration (FDA) has approved a PD-L1 companion diagnostic test for patients with esophageal cancer or ...
Alphamab Oncology (stock code: 9966.HK) announced that the first patient has been successfully dosed in the phase I clinical study (study code: JSKN027-101) of JSKN027, an independently developed ...
Dr. Miranda Gogishvili, a medical oncologist at the High Technology Medical Center, University Clinic in Tbilisi, Georgia, ...
JCO Precision Oncology Conversations features discussions with leading authors of JCO Precision Oncology articles, hosted by Dr. Abdul Rafeh Naqash. Join our experts in engaging conversations as they ...
Experts discuss the evolving role of PD-L1 in guiding perioperative treatment decisions for resectable NSCLC and review the pivotal CheckMate 816 trial, which established neoadjuvant nivolumab plus ...
The role of determining HER2neu status in patients with gastric cancer. Advanced signet ring cell type gastroesophageal cancers in Latin American patients age 40 and below: A summary of one tertiary ...
AI may calculate PD-L1 scores for non-small cell lung cancer more accurately than manual assessment, results of an analysis ...
Findings of the BEATcc trial suggest PD-L1 status is not a reliable biomarker for guiding immunotherapy selection in patients with recurrent or metastatic cervical cancer, potentially simplifying ...
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced that KEYTRUDA® (pembrolizumab), in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results